Alysheba

Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.

5 partners are named across this firm’s filings, 5 of them on a fund it is deploying now.

Classified sectors of Alysheba’s own portfolio companies, based on 3 with a verified or cited source.

• Biotech & pharma1 · 33%
• Climate & energy1 · 33%
• Medical devices1 · 33%

Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Alysheba’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.

No other firm shares a filed board seat with Alysheba yet. That is a gap in what we have read, not a claim that Alysheba invests alone.

A shared board seat: a company where filings name a Alysheba partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.